- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Annexin Pharmaceuticals AB: Annexin investigates a three-day ANXV treatment regimen in patients with RVO | 42 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces a shortening of the ANXV treatment regimen from five to three days at the same dose level. A three-day treatment is expected to strengthen the commercial value... ► Artikel lesen | |
| 11.05. | Annexin Pharmaceuticals AB: Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study | 151 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the company has received an approval for a clinical trial with the drug candidate ANXV by the German Medicines Agency Bundesinstitut für Arzneimittel... ► Artikel lesen | |
| 22.04. | Annexin Pharmaceuticals AB: Annexin accelerates patient recruitment - five patients treated | 127 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO)... ► Artikel lesen | |
| 13.04. | Annexin Pharmaceuticals AB: Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026 | 149 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20 million... ► Artikel lesen | |
| 04.02. | Annexin Pharmaceuticals AB: Favourable findings in Annexin's ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion | 481 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion... ► Artikel lesen | |
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 235 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen | |
| 16.09.25 | Annexin Pharmaceuticals AB: Annexin appoints world-leading ophthalmology experts to Medical Advisory Board | 220 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical... ► Artikel lesen | |
| 07.08.25 | Annexin Pharmaceuticals AB: Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO | 310 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate ANXV... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 28.05.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 28.05.2025 | 1.597 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.05.2025
Aktien
1 CNE100006XS6 Jiangsu Hengrui Pharmaceuticals... ► Artikel lesen | |
| 27.05.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.05.2025 | 779 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.05.2025ISIN NameCA42841L1085 HI-VIEW... ► Artikel lesen | |
| 27.05.25 | XFRA ISIN CHANGE | 763 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA82888R1055 Simply Better Brands Corp. 27.05.2025 CA89778A1003 Trubar Inc. 28.05.2025 Tausch 1:1SE0009664154 Annexin... ► Artikel lesen | |
| 27.05.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2025 | 843 | Xetra Newsboard | Das Instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2025 The instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| 26.05.25 | Reverse Split and Change of ISIN for Annexin Pharmaceuticals AB | 637 | GlobeNewswire | Referring to the press release from Annexin Pharmaceuticals AB's on 21 May, the company will carry out a reverse stock split in relations 1:100. The share will be traded under new ISIN code with... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 35,490 | -0,20 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| HCW BIOLOGICS | 2,440 | +0,41 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,890 | 0,00 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| COGENT BIOSCIENCES | 32,925 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,110 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| DYNE THERAPEUTICS | 17,560 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | - 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,430 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | ||
| TANGO THERAPEUTICS | 21,060 | -0,09 % | Tango Therapeutics Shares Fall 17% | ||
| RELAY THERAPEUTICS | 13,030 | +0,08 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| METAVIA | 2,895 | +0,17 % | MetaVia Inc.: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update | 48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit
Key Milestone... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 335,45 | -0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ERASCA | 11,125 | +0,04 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,32 | -0,09 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| ENLIVEN THERAPEUTICS | 41,860 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 36,890 | +0,05 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
Das Unternehmen ANNEXIN PHARMACEUTICALS AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.